Eco-design and medicine: Opportunities to implement eco-design in the pharmaceutical R&D process

Duc-Nam Luu, Hervé Gachet, Claus-Jürgen Maier, Nicolas Maranzana () and Améziane Aoussat ()
Additional contact information
Duc-Nam Luu: LCPI - Laboratoire Conception de Produits et Innovation - Arts et Métiers Sciences et Technologies
Hervé Gachet: Sanofi Gentilly - Sanofi Gentilly
Claus-Jürgen Maier: Sanofi-Aventis Deutschland GmbH [Francfort, Allemagne]
Nicolas Maranzana: LCPI - Laboratoire Conception de Produits et Innovation - Arts et Métiers Sciences et Technologies
Améziane Aoussat: LCPI - Laboratoire Conception de Produits et Innovation - Arts et Métiers Sciences et Technologies

Post-Print from HAL

Abstract: The pharmaceutical sector has the societal duty to make medical healthcare products both available and affordable. But like any human activity, it is not neutral in terms of environmental impact. Therefore, and like any industry, the pharmaceutical sector needs to consider the environmental aspects into its product design and activities in order to reach a sustainable production and consumption patterns, as defined by the Sustainable Development Goal (SDG) 12 of the United Nations. With a holistic perspective, the eco-design concept is an approach that aims to integrate environmental aspects into product design. To contribute to the SDGs, the pharmaceutical industry needs to consider the environmental impacts of its products. Usually, experts within Research & Development (R&D) do not have the proper level of knowledge to integrate the environmental aspects, in a Lifecycle perspective, into their decision making. Even so, those parameters are not yet part of the New Product Development (NPD) process of the medicine product. With those elements in mind, the aim of this paper is to understand which phases of the pharmaceutical R&D process represent an opportunity to eco-design such products. We proposed two qualitative experimentations with, first interviewing ten practitioners of R&D; and second, with an assessment of the medicine NPD process and related deliverables, based on LCA results. The use of such results to investigate potential key contributors during NPD stages does not seem to be explored yet, especially for the pharmaceutical sector. Results show that eco-design approaches can be performed all along the development of a pharmaceutical product. Main eco-design levers appear in parallel to the clinical phases 2a and 2b, in other words, when the tests on the final marketed form are initiated.

Keywords: Building and Construction; Sustainability and the Environment; Renewable Energy; General Environmental Science; Strategy and Management; Industrial and Manufacturing Engineering (search for similar items in EconPapers)
Date: 2022
New Economics Papers: this item is included in nep-env
Note: View the original document on HAL open archive server: https://hal.science/hal-03794792v1
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in Journal of Cleaner Production, 2022, 365, pp.132785. ⟨10.1016/j.jclepro.2022.132785⟩

Downloads: (external link)
https://hal.science/hal-03794792v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03794792

DOI: 10.1016/j.jclepro.2022.132785

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().